P
Patrick Essletzbichler
Researcher at Austrian Academy of Sciences
Publications - 14
Citations - 8959
Patrick Essletzbichler is an academic researcher from Austrian Academy of Sciences. The author has contributed to research in topics: CRISPR & Cas9. The author has an hindex of 11, co-authored 13 publications receiving 5939 citations. Previous affiliations of Patrick Essletzbichler include Massachusetts Institute of Technology & McGovern Institute for Brain Research.
Papers
More filters
Journal ArticleDOI
Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.
Bernd Zetsche,Jonathan S. Gootenberg,Omar O. Abudayyeh,Ian Slaymaker,Kira S. Makarova,Patrick Essletzbichler,Sara E. Volz,Julia Joung,John van der Oost,Aviv Regev,Aviv Regev,Eugene V. Koonin,Feng Zhang +12 more
TL;DR: In this paper, the authors characterized Cpf1, a putative class 2 CRISPR effector, which is a single RNA-guided endonuclease lacking tracrRNA and utilizes a T-rich protospacer-adjacent motif.
Journal ArticleDOI
Nucleic acid detection with CRISPR-Cas13a/C2c2
Jonathan S. Gootenberg,Omar O. Abudayyeh,Jeong Wook Lee,Patrick Essletzbichler,Aaron J. Dy,Aaron J. Dy,Julia Joung,Vanessa Verdine,Nina M. Donghia,Nichole M. Daringer,Catherine A. Freije,Catherine A. Freije,Cameron Myhrvold,Cameron Myhrvold,Roby P. Bhattacharyya,Jonathan Livny,Aviv Regev,Aviv Regev,Eugene V. Koonin,Deborah T. Hung,Pardis C. Sabeti,James J. Collins,Feng Zhang +22 more
TL;DR: A Cas13a-based molecular detection platform, termed Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK), is used to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype human DNA, and identify mutations in cell-free tumor DNA.
Journal ArticleDOI
RNA targeting with CRISPR-Cas13.
Omar O. Abudayyeh,Jonathan S. Gootenberg,Patrick Essletzbichler,Shuo Han,Julia Joung,Joseph J. Belanto,Vanessa Verdine,David Benjamin Turitz Cox,Max J. Kellner,Aviv Regev,Aviv Regev,Eric S. Lander,Eric S. Lander,Eric S. Lander,Daniel F. Voytas,Alice Y. Ting,Feng Zhang +16 more
TL;DR: It is demonstrated that the class 2 type VI RNA-guided RNA-targeting CRISPR–Cas effector Cas13a (previously known as C2c2) can be engineered for mammalian cell RNA knockdown and binding and is established as a flexible platform for studying RNA in mammalian cells and therapeutic development.
Nucleic acid detection with CRISPR-Cas13a/C2c2
Jonathan S. Gootenberg,Omar O. Abudayyeh,Jeong Wook Lee,Patrick Essletzbichler,Aaron J. Dy,Aaron J. Dy,Julia Joung,Vanessa Verdine,Nina M. Donghia,Nichole M. Daringer,Catherine A. Freije,Catherine A. Freije,Cameron Myhrvold,Cameron Myhrvold,Roby P. Bhattacharyya,Jonathan Livny,Aviv Regev,Aviv Regev,Eugene V. Koonin,Deborah T. Hung,Pardis C. Sabeti,James J. Collins,Feng Zhang +22 more
TL;DR: In this paper, a CRISPR-Dx-based molecular detection platform, termed Specific High-Sensitivity Enzymatic Reporter Unlocking (SHERLOCK), was proposed to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype human DNA, and identify mutations in cell-free tumor DNA.
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Bernd Zetsche,Jonathan S. Gootenberg,Omar O. Abudayyeh,Ian Slaymaker,Kira S. Makarova,Patrick Essletzbichler,Sara E. Volz,Julia Joung,John van der Oost,Aviv Regev,Aviv Regev,Eugene V. Koonin,Feng Zhang +12 more
TL;DR: It is demonstrated that Cpf1 mediates robust DNA interference with features distinct from Cas9, and this mechanism of interference broadens the understanding of CRISPR-Cas systems and advances their genome editing applications.